Iso-Dose Line Prescription for Brain Metastases Radiotherapy

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for multiple brain metastases treatment planning lack support for iso-dose line prescriptions and risk structure sparing, limiting dose prescription to a single value and failing to control dose constraints effectively, especially for vital organs.

Innovation Solution

A computer-implemented method that acquires patient and target data, determines beam shaping device configurations, and optimizes treatment plans using iso-dose line prescriptions and risk structure sparing, allowing for dynamic conformal arcs with adjustable margins and arc-weights to ensure precise dose delivery to metastases while minimizing dose to normal tissue and vital organs.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If a single dose prescription value is used for multiple brain metastases, then the treatment planning process is simpler, but dose homogeneity across different metastases cannot be controlled

Engineering Contradiction:
Improvetreatment planning processVSAvoiddose homogeneity
Core Design Contradiction:
Ease of operationVSManufacturing precision

Solution Approach 1:

The patent divides the treatment planning into separate iso-dose line prescriptions for each metastasis target. Instead of applying a single dose value to all targets, the system allows independent dose specification for each metastasis, enabling precise control of dose homogeneity while maintaining manageable complexity through structured segmentation of the planning process.

Inventive Principle:
Principle #1Segmentation

2Device complexity

If dose constraints to risk structures are not controlled, then the treatment planning is less complex, but vital organs receive excessive radiation dose

Engineering Contradiction:
Improvetreatment planning complexityVSAvoidradiation dose to vital organs
Core Design Contradiction:
Device complexityVSObject-affected harmful factors

Solution Approach 1:

The patent implements local quality control by allowing different dose constraints to be specified for different risk structures. Each vital organ can have its own dose limit parameters, enabling the system to protect sensitive structures with appropriate dose restrictions while maintaining overall treatment plan feasibility without excessive complexity.

Inventive Principle:
Principle #3Local quality

3Manufacturing precision

If iso-dose line prescriptions with multiple dose values are implemented, then dose homogeneity control is improved, but the treatment planning complexity increases

Engineering Contradiction:
Improvedose homogeneity controlVSAvoidtreatment planning complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent introduces dynamic adjustability in the treatment planning system by allowing operators to specify multiple dose values for different iso-dose lines around each metastasis. The system dynamically adapts the treatment plan based on these prescriptions, providing precise dose homogeneity control while managing complexity through automated optimization algorithms that adjust plan parameters in response to the specified dose requirements.

Inventive Principle:
Principle #15Dynamics

4Object-affected harmful factors

If risk structure sparing is implemented, then dose to vital organs is reduced, but the optimization process becomes more complex

Engineering Contradiction:
Improvedose to vital organsVSAvoidoptimization process
Core Design Contradiction:
Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-defining risk structures and their dose constraints before the optimization process begins. The system prepares the optimization framework with predetermined protective measures for vital organs, allowing the optimization algorithm to work within established boundaries rather than dealing with unconstrained complexity, thus reducing dose to vital organs while managing optimization complexity through pre-planned constraints.

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentUS20230139690A1Method for Treatment of Multiple Brain Metastases Based on Iso-Dose Line Prescriptions
Publication Date: 2023.05.04 BRAINLAB AG
  • US20230139690A1 patent drawing
  • US20230139690A1 patent drawing
  • US20230139690A1 patent drawing

AI summary

Disclosed is a computer-implemented method of determining a treatment plan, encompassing acquiring patient image data, acquiring target data describing targets, acquiring position data describing control points which define one or more arcs, and determining target projection data which describes outlines of the target in a beam's-eye view. Margin data is acquired. For the outlines, margins are applied to determine auxiliary outlines. Beam shaping device data is determined describing configurations of the collimator leaves so that irradiation of the auxiliary outlines is enabled. Based on these configurations, the irradiation amount is simulated for voxels of the patient image data. Constraints to be fulfilled by the treatment plan may be set. Configurations of blockings, arc-weights and margins are proposed. Only different combinations of these parameters are proposed while additional possible parameters are neglected. An optimization algorithm is used to minimize an objective function. The best configuration is selected as the treatment plan.